Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

North Charleston, South Carolina Clinical Trials

A listing of North Charleston, South Carolina clinical trials actively recruiting patient volunteers.

RESULTS

Found (26) clinical trials

Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

The purpose of this study is to see if anti-platelet therapy combined with anti-PD-1 immunotherapy can cause a more favorable immunologic response thatn with immunotherapy alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Phase

5.28 miles

Learn More »

Study Designed to Assess the Safety Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

Part 1 of this trial will enroll healthy volunteers into a single ascending dose (SAD), multiple ascending dose (MAD), and Food Effect (FE) treatment groups. The SAD treatment group is comprised of at least 3 ascending dose level cohorts where healthy adult subjects will be randomized to receive a single ...

Phase

5.28 miles

Learn More »

A "Window Trial" on Boswellia for Breast Cancer and Colon Cancer Primary Tumors

To determine whether oral administration of Boswellia serrata causes biological changes related to angiogenesis (CD31), apoptosis (DNA fragmentation), and cell proliferation (Ki67) in primary tumors of breast or colon cancer patients.

Phase

5.28 miles

Learn More »

Trial of Tolcapone With Oxaliplatin for Neuroblastoma

The purpose of this research study is to evaluate an investigational drug (Tolcapone) alone and in combination with oxaliplatin, for relapsed and refractory neuroblastoma. Tolcapone is approved by the U.S. Food and Drug Administration (FDA) for adults, but is an investigational drug in this study because it has not been ...

Phase

5.28 miles

Learn More »

Transcranial Direct Current Stimulation (tDCS) and Task-Specific Practice for Post-stroke Neglect

Unilateral neglect (neglect) is common after stroke and is characterized by an inattention to one side of the body or environment. There is growing evidence that disconnections to fronto-parietal neural networks in the lesioned hemisphere not only cause neglect, but also cause these same networks to be hyperexcited in the ...

Phase

5.28 miles

Learn More »

Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers

The primary objectives in the dose escalation phase are to evaluate safety and pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of REGN3767 as monotherapy and in combination with REGN2810 in patients with advanced malignancies, including lymphoma. The primary objectives in the dose expansion phase are ...

Phase

5.28 miles

Learn More »

Study Assessing the Safety Tolerability Pharmacokinetics Food Effect and Drug-Drug Interactions of PTI-801 in Healthy Volunteers and Safety Tolerability and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis

PART 1 The SAD treatment group is comprised of three cohorts where HV will be randomized to either PTI-801 or placebo. Following the conclusion of at least three SAD cohorts, a set of HV will participate in an assigned MAD treatment group. The MAD treatment group is comprised of three ...

Phase

5.28 miles

Learn More »

A Study of ONO-7475 in Patients With Acute Leukemias

This study will determine the safety and maximum tolerated dose of ONO-7475 in patients with relapsed or refractory acute leukemia and evaluate the efficacy of ONO-7475 in patients with newly diagnosed AML

Phase

5.28 miles

Learn More »

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT). Cycle length will be 21 days in Cohorts A ...

Phase

5.28 miles

Learn More »

Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma

The purpose of this study is to determine the safety and tolerability of adding oral azacitadine to the chemotherapy combination R-ICE. This study will also look at whether or not disease outcomes improve with the combination.

Phase

5.28 miles

Learn More »